Loading...
XHKG8329
Market cap34mUSD
Dec 23, Last price  
0.15HKD
1D
-4.38%
1Q
14.18%
Jan 2017
-68.45%
IPO
-54.33%
Name

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Chart & Performance

D1W1MN
XHKG:8329 chart
P/E
10.45
P/S
0.24
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
4.19%
Revenues
1.06b
+7.92%
20,181,00016,160,00016,310,0003,696,00038,256,000474,652,000530,458,000611,666,000648,268,000721,346,000759,111,000790,286,000867,123,0001,080,871,0001,031,369,000838,805,000986,691,0001,064,861,000
Net income
24m
-55.60%
-25,967,000-21,167,000-30,595,000-37,476,000-30,104,00021,686,00024,298,00035,855,00033,174,00021,055,00062,692,00050,257,00048,089,00059,719,00036,592,00035,958,00054,346,00024,127,000
CFO
54m
-12.31%
5,493,000-32,054,00010,723,00038,934,00063,266,000-63,189,00051,628,00028,991,00039,111,00062,308,00082,854,00055,783,00025,033,00060,352,00093,644,000-69,924,00061,220,00053,686,000
Earnings
Mar 25, 2025

Profile

Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In addition, the company manufactures herbal medicines and generic drugs products, as well as medical devices. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
URL
https://www.interlong.com/
IPO date
Sep 12, 2005
Employees
1,453
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,064,861
7.92%
986,691
17.63%
838,805
-18.67%
Cost of revenue
1,015,080
909,236
808,556
Unusual Expense (Income)
NOPBT
49,781
77,455
30,249
NOPBT Margin
4.67%
7.85%
3.61%
Operating Taxes
16,148
18,431
4,804
Tax Rate
32.44%
23.80%
15.88%
NOPAT
33,633
59,024
25,445
Net income
24,127
-55.60%
54,346
51.14%
35,958
-1.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
85,916
88,209
105,074
Long-term debt
5,612
9,238
5,177
Deferred revenue
589
589
940
Other long-term liabilities
Net debt
(300,678)
(222,651)
(146,893)
Cash flow
Cash from operating activities
53,686
61,220
(69,924)
CAPEX
(15,214)
(19,714)
(15,073)
Cash from investing activities
60,897
10,757
(181,566)
Cash from financing activities
(32,475)
(9,023)
66,749
FCF
7,224
46,228
(70,878)
Balance
Cash
382,206
350,098
311,144
Long term investments
10,000
(30,000)
(54,000)
Excess cash
338,963
270,763
215,204
Stockholders' equity
461,338
638,954
578,050
Invested Capital
767,494
814,770
829,252
ROIC
4.25%
7.18%
4.24%
ROCE
4.38%
6.97%
2.83%
EV
Common stock shares outstanding
1,678,000
1,678,000
1,678,000
Price
0.16
-4.65%
0.17
-7.03%
0.19
-44.78%
Market cap
275,192
-4.65%
288,616
-7.03%
310,430
-44.78%
EV
82,527
375,721
466,735
EBITDA
83,425
113,399
60,517
EV/EBITDA
0.99
3.31
7.71
Interest
5,574
7,032
4,596
Interest/NOPBT
11.20%
9.08%
15.19%